Adrijana Vinter

Global Head of Drug Discovery, Member of the Management Board at Selvita

https://www.linkedin.com/in/adrijana-vinter-28600211/

adrijana_z@yahoo.com

+385 91 265 55 27, Zagreb, Croatia

Krakow, Poland

PROFILE

Global life sciences executive with more than 15 years of experience leading multidisciplinary, multicultural organizations across Europe, the U.S., and Japan. Currently serving as Global Head of Drug Discovery and Management Board Member at Selvita, I oversee a 500+ member organization spanning chemistry, DMPK, biochemistry, in vitro/in vivo pharmacology, bioinformatics, and translational sciences.
I specialize in aligning scientific, analytical, and business functions through insight-driven leadership — transforming complex data into strategic intelligence that drives innovation and growth. My track record includes leading post-merger integrations, managing cross-regional teams, embedding AI and bioinformatics capabilities, and introducing next-generation technologies such as spatial omics and 3D translational models. Recognized for developing people, building future-ready capabilities, and unifying diverse teams under a shared strategic vision.

From the scientific area, my experience is in TA of immunology and infection. I have been actively working on many drug discovery projects but also overseeing them.

I am active in different initiatives for mentoring and empowering young women professionals and start-up companies in healthcare sector. I am also supporting development local scientific community in Croatia and have introduced national scholarship program for scientists in Selvita.

I am frequently t invited lecturer and speaker at international scientific and industry conferences and actively promote cross-sector collaboration and knowledge sharing between science and business.

EDUCATION

2010 - 2012	Cotrugli Business School, Master of Business Administration
2004 - 2011	University of Zagreb, Faculty of science, PhD Organic Chemistry
1997 - 2002	University of Zagreb, Faculty of science, MSc Chemistry

Languages

Croatian	native
English	fluent
German	basic
Italian	fluent
Slovenian	fluent

EXPERIENCE

Selvita SA
2022 > Current
Global Head of Drug Discovery and Management Board Member

Selvita d.o.o.
2022 > Current
President of the Management Board

Fidelta
2017 > 2022
CEO and CCO (Chief Commercial Officer)

Fidelta
2015 > 2017
CCO (Chief Commercial Officer)

Fidelta
2013 > 2015
Business Development Manager

Fidelta
2013 > 2013
Business Development Officer

Galapagos
2010 > 2013
Principal Scientist, Medicinal Chemistry

GlaxoSmithKline
2006 > 2010
Senior Scientist, Medicinal Chemistry

Pliva
2002 > 2006
Scientist, Medicinal Chemistry

PUBLICATIONS

Ester linked macrolides useful for the treatment of microbial infectionsester linked macrolides useful for the treatment of microbial infections, Patent WO/2005/108412 · Jan 1, 2005

Vinter, A., Avdagic, A., Stimac, V., Palej, I., Cikos, A., Sunjic, V. and Alihodzic, S., 2009. An expeditious method for the preparation of 2-hydroxy-1, 4-dioxane and its use in reductive alkylation of amines. *Synthesis*, pp.255-258.

Stimac, V., Matanović Skugor, M., Palej Jakopović, I., Vinter, A., Ilijaš, M., Alihodžić, S. and Mutak, S., 2010. Initial Scale-Up and Process Improvements for the preparation of a lead antibacterial macrolone compound. *Organic Process Research & Development*, 14(6), pp.1393-1401.

Fajdetić, A., Vinter, A., Paljetak, H.Č., Padovan, J., Jakopović, I.P., Kapić, S., Alihodžić, S., Filić, D., Modrić, M., Košutić-Hulita, N. and Antolović, R., 2011. Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. *European journal of medicinal chemistry*, 46(8), pp.3388-3397.

Wittine, K., Antolović, R., Jelić, D., Bracanović, S., Cetina, M., Andjelkovic, U., Wittine, O., Pavelić, S.K. and Vinter, A., 2020. Thienochromene derivatives inhibit pSTAT1 and pSTAT5 signaling induced by cytokines. *Bioorganic & Medicinal Chemistry Letters*, 30(18), p.127415.

Kovačević, T., Nujić, K., Cindrić, M., Dragojević, S., Vinter, A., Hozić, A. and Mesić, M., 2023. Different chemical proteomic approaches to identify the targets of lapatinib. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 38(1), p.2183809.

A.Vinter and I. Grgicevic, Artificial intelligence in GPCR drug discovery: A paradigm shift in computational pharmacology, In book: *Reference Module in Chemistry, Molecular Sciences and Chemical Engineering*, 2025

https://doi.org/10.1016/B978-0-443-29808-0.00047-9